Emea 1

The European Agency for the Evaluation of Medicinal Products
7 Westferry Circus, Canary Wharf, London E14 4HB, UK

Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8447
E_Mail: [email protected] http://www.eudra.org/emea.html
EMEA 1998
Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
ENROFLOXACIN
SUMMARY REPORT (1)
1. Enrofloxacin is a fluoroquinolone antibiotic which acts by inhibition of bacterial DNA-gyrase. It is
administered to cattle, pigs, chickens and turkeys to control bacterial infections caused by sensitive
organisms.
2. In rats, enrafloxacin was well absorbed after oral administration. It was rapidly excreted in the bile
and urine, mostly as enrofloxacin and the metabolite ciprofloxacin, together with relatively small
amounts of other metabolites. Ciprofloxacin was the only metabolite of significance which was
found in the tissues and excreta of the species studied. Ciprofloxacin is widely used in human
medicine and was reported to be well absorbed after oral administration to humans; peak plasma
concentrations were achieved within 1-2 hours and the half-life was 3.5-4.5 hours. Humans excreted
30-50% of an oral dose of ciprofloxacin in the urine within 24 hours of administration and
significant amounts were also excreted in faeces.
3. Enrofloxacin was of low acute toxicity. In a 13-week study in the rat in which up to 7500 mg/kg
enrofloxacin was administered in the feed, the findings attributable to treatment included :
reduced bodyweight gain (in both sexes receiving the top dose),
caecal distension with no corresponding microscopic alterations (a common finding in rats
given large doses of antibiotics),
histopathological changes in the knee joint (in 3 out of 30 animals receiving the top dose), and
in male rats receiving the top dose, dark, round or oval cells in the epididymides (12 out of 15
rats) and in the seminiferous tubules (5 out of 15 rats). These cells probably represented a
degenerating or necrotic "cap phase" spermatid.
The no-effect level for the study was 300 mg/kg (equivalent to 40 mg/kg bw).
4. A further study was carried out which incorporated various "recovery periods", in order to explain
the testicular effects. In rats not included in a recovery phase, no abnormal spermatozoa were found
at the lowest dose administered (125 mg/kg equivalent to 10 mg/kg bw per day). No abnormal
spermatozoa were found in the seminiferous tubules of any animal at the end of the 90-day recovery
phase and recovery of the epididymides was also apparent. This study indicated that the effects on
the testes were reversible.
5. Similar effects on the male reproductive tract were observed in several other studies in rats including
a multigeneration study in which reproductive performance was impaired at the top dose level of
7500 mg/kg but not at 500 mg/kg.
However similar effects on spermatogenesis mere not observed in repeat dose studies in other
species.
6. Degenerative changes, typical of those induced by fluoroquinolone antibiotics, were found in the
articular cartilage after administration of enrofloxacin to immature animals such as calves, piglets
and puppies. Dogs were the species most sensitive to this effect and a NOEL of 3 mg/kg bw per day
was established for arthropathy in a 13-week repeat dose study in which the dogs were 3-months old
at the start.
2/3
EMEA 1998
7. Enrofloxacin was not teratogenic in either the rat or the chinchilla and NOELs for foetotoxicity of 50
and 25 mg/kg bw per day, respectively, were established.
8. Enrofloxacin produced no increase in revertants in an bacterial assay for gene mutation though only
very low drug concentrations could be tested because of the high toxicity shown towards the tester
strains of bacteria. Sporadic increases in mutant frequency were observed in a CHO HGPRT
forward mutation assay but without any evidence of a dose-response and an in vitro UDS assay gave
negative results. There was a small but dose-related increase in SCEs per metaphase in an in vivo
SCE assay in hamster bone marrow but the increase was not statistically-significant and no evidence
of mutagenicity was found in either an in vivo mouse micronucleus test nor in an in vivo
cytogenetics assay in rat bone marrow.
9. In a rat carcinogenicity study, the incidence of endocardial tumours was elevated in females
receiving the top dose. When the incidence of endocardial tumours was combined with the incidence
of proliferative lesions, the difference from the controls was significant in both sexes receiving the
top dose. Also in this study, the incidence of bile duct hyperplasia was increased in a dose-related
manner. However an independent review of the histology slides indicated that both the endocardial
neoplasms and the Schwann cell-like hyperplasia were not associated with administration of
enrofloxacin. In a second carcinogenicity study in the same strain of rat, no neoplastic changes
attributable to treatment with enrofloxacin were observed. However because evidence of bile duct
hyperlasia was apparent at the lowest dose level tested, a third study was carried out;
histopathological examinations after 12 months showed no evidence of a dose-related increase in bile
duct hyperplasia at dose levels of up to 50 mg/kg in the diet. Although the incidence of malignant
lymphoma was increased in treated groups in a carcinogenicity study in the mouse, the incidence
was within the historical control range. It was concluded from these studies that enrofloxacin was not
carcinogenic.
10. No data were provided on the effects of enrofloxacin in humans. The main metabolite, ciprofloxacin,
has been widely used in human medicine for several years; the side effects were reported to include
gastrointestinal disturbances, some hypersensitivity reactions and crystalluria. Ciprofloxacin is
contra-indicated in young children and in lactating mothers because of the risk of arthropathy.
11. Data on the in vitro sensitivity of several species of human gastrointestinal flora indicated that E. coli
was the most sensitive to enrofloxacin with a MIC range of 0.015-0.03 g/ml. MIC values in the
same numerical range were also obtained for the metabolite ciprofloxacin. An ADI of 0-0.3125
g/kg bw per day for a 60 kg person (a maximum ADI of 18.75 g/person) was derived, using the
lowest MIC of 0.015 g/ml corrected by a factor of 10 to obtain the concentration without effect on
the human gut flora, and assuming :
a daily faecal bolus of 150 g,
a "safety factor" of 10, and
12% for the quantity of the ingested amount which would be available to the bacteria at the
distal part of the intestine.
3/3
EMEA 1998
12. Residue depletion in all tissues of all food producing species was very rapid. In pigs, residues in
tissues consisted chiefly of enrofloxacin with smaller amounts of ciprofloxacin. 12 hours after
withdrawal of the drug, 80-90% of the total residue present consisted of enrofloxacin +
ciprofloxacin. In calves, residues consisted of almost equal amounts of enrofloxacin and
ciprofloxacin. Residues in poultry also consisted of a mixture of the two compounds.
The following MRLs were recommended:
Marker residue Animal species MRLs Target tissues
sum of enrofloxacin +
ciprofloxacin
Bovine, porcine,
poultry
30 g/kg muscle, liver,
kidney
The MRLs recommended above would result in a daily maximum intake of 15 g active ingredients
based on a daily food intake of 500 g of combined tissue. This is within the ADI estimated in
paragraph 11 (above).
13. An analytical method for the determination of both enrofloxacin and ciprofloxacin was developed,
based on HPLC with fluorescence detection. A limit of determination of l0 g/kg was achievable for
both substances, for most edible tissues.

Emea 1

Uploaded by

Copyright:

Available Formats

Emea 1

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Emea 1

Uploaded by

Copyright:

Available Formats

The European Agency for the Evaluation of Medicinal Products

7 Westferry Circus, Canary Wharf, London E14 4HB, UK

You might also like